Digital
1st March 2024
This Pharmaceutical Marketing Society article is based on a recent discussion between three members of the Digital Interest Group.
This Pharmaceutical Marketing Society article is based on a recent discussion between three members of the Digital Interest Group.
This article provided an overview of various thought-provoking articles published by the PM Society Digital Interest Group (DIG) throughout 2023.
This article is the 13th in a series produced by the Digital Interest Group. It is an exciting time of year looking forward to next year’s projects with a new budget to spend, or perhaps quickly using up the remainder of this year’s budget before Scrooge in procurement takes it back.
This article is the 12th in a series produced by the Pharmaceutical Marketing Society’s Digital Interest Group.
Delivering relevant, valuable and timely content at scale to healthcare professionals (HCPs) still proves a challenge for many global companies.
But why?
The phrase “AI will not replace you, a person using it will” probably sums up how those working in #pharmamarketing and #medicalcommunications fields think about the acceleration we’ve seen in #AI since last November.
By 2025, 50% of content will be modular, according to The Veeva Executive Content Innovation Council.
Pharmaceutical companies have two main choices when looking to build and maintain relationships with doctors and other healthcare professionals (HCPs):
This article explores what this means for medical education. What is the future (and the very real present) that we should be recognising to better support the education of HCPs?
The world has undeniably undergone a digital transformation, with all industries now offering us as consumers a choice of how we engage with them. Unfortunately the pharmaceutical industry is a little late to the party.